Sydney, Australia 13 September 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”, “the Company”), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce the appointment of Dr Jeffrey Norenberg as Chief Scientific Officer (CSO), effective immediately. Dr Norenberg has more…
Sydney, Australia 12 September 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce that the patent application covering Clarity’s optimised Prostate Specific Membrane Antigen (PSMA) targeting agent, SAR-bisPSMA, has been Granted in China.…
Sydney, Australia 5 September 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce that the US-based diagnostic 64Cu SAR-Bombesin trial (SABRE NCT05407311)1 for patients with PSMA-negative prostate cancer is open for recruitment. SABRE (Copper-64…
Sydney, Australia 23 August 2022 Highlights Cohort 2 completed in participants with neuroblastoma who received therapy with 67Cu SARTATE™ at a dose of 175MBq/kg body weight No Dose Limiting Toxicities (DLTs) have been reported in cohort 1 and cohort 2 Safety Review Committee (SRC) has recommended the trial continues with the dose escalation phase as…
Sydney, Australia 22 August 2022 Highlights Diagnostic investigator-initiated trial (IIT) with one of Clarity’ core products, SAR-Bombesin, commenced at St Vincent’s Hospital Sydney, led by Prof Louise Emmett. The Phase II IIT builds on the data generated in PSMA-negative prostate cancer patients at St Vincent’s Hospital imaged under the Therapeutic Goods Administration (TGA) Special Access…
Sydney, Australia 11 August 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, has signed a supply agreement with 3D Imaging LLC. (3DI), a Contract Development and Manufacturing Organisation (CDMO), covering Clarity’s diagnostic 64Cu SAR-bisPSMA product. The new agreement, effective on August 11th, 2022,…
Sydney, Australia 9 August 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, and Evergreen Theragnostics, Inc. (“Evergreen”), a radiopharmaceutical contract development and manufacturing organisation, are pleased to announce that the companies have expanded their Targeted Copper Theranostics (TCTs) manufacturing agreement to include next-generation…
Sydney, Australia 20 July 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce the completion of recruitment for the Phase I PROPELLER diagnostic trial evaluating its 64Cu-SAR-bisPSMA product candidate in patients with untreated, confirmed prostate cancer, scheduled for radical prostatectomy.…
Sydney, Australia 29 June 2022 Highlights Professor Louise Emmett joins Clarity’s Scientific Advisory Board (SAB) She is deeply embedded in Australia’s multidisciplinary clinical development and cancer research efforts Professor Emmett will continue to be highly active and influential in progressing Clarity’s SAR Technology as both a collaborator and now as a SAB member Follows the…
Sydney, Australia 6 June 2022 Highlights IND approval received for SAR-Bombesin product, enabling a Phase II “SABRE” imaging trial to detect prostate cancer in up to 50 PSMA-negative participants in the US Approximately 20% of prostate cancer patients with biochemical recurrence are PSMA-PET negative and therefore unsuitable for the currently approved PSMA targeting agents, presenting…